Amgen has filed a legal action in California state court against Bay Area biosimilar maker Coherus Biosciences, Inc, alleging that since 2014 Coherus has engaged in a “massive conspiracy” to steal trade secrets for Amgen’s reference biologic pegfilgrastim (Neulasta). The drug, a pegylated form of recombinant human granulocyte colony-stimulating factor, is indicated to reduce the incidence of infection in patients with non-myeloid malignancies who are receiving myelosuppressive anticancer agents. Coherus’ biosimilar to pegfilgrastim (CHS-1701) is currently scheduled for a June 9, 2017, regulatory hearing at the FDA concerning its approval.
The lawsuit asserts that Coherus induced multiple Amgen employees to breach confidentiality agreements regarding Amgen’s pipeline in order to gain proprietary knowledge, allegedly receiving such information on “stolen” USB drives. This included sensitive Amgen standard operating procedures, lab notebook pages, validated analytical methods, method development reports, specifications, documents reflecting process optimization work, cost calculators, and pricing and contracting strategies. Amgen is seeking restitution and damages. The lawsuit also names former Amgen employees, including Howard S. Weiser, currently executive director at Coherus, as having violated trade secrets.
Coherus categorically rejected the allegations as baseless and accused Amgen of using the lawsuit to prevent potential competition from the biosimilar product, should it be approved. Danny Lanfear, president and CEO of Coherus, said the action is without merit and the company would defend against it vigorously. “Coherus believes this lawsuit is best understood as an effort by Amgen to use baseless litigation in an effort to delay Coherus as a competitor in the pegfilgrastim market,” he said in a statement.
Lanfear went on to deny that his company needed Amgen’s proprietary information to compete or be successful, adding that he is proud of Coherus’ novel clinical development strategy and novel clinical study designs—none of which were ever performed at Amgen and are not Amgen’s intellectual property. Barclays analysts said the alleged violations occurred well after Coherus developed CHS-1701.
Coherus is also developing a biosimilar of Amgen’s rheumatoid arthritis treatment etanercept (Enbrel) and Abbvie’s adalimumab (Humira).
Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability
May 9th 2024As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.